stockrowLongeveron Inc.
LGVN Healthcare Biotechnology
Longeveron Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, down 49.9% from fiscal 2024.
- Revenue
- −9.18%
- EPS
- +42.4%
- Free cash flow
- −49.1%
Quarter to June 2026, against a year earlier
Follow LGVN
Alert me
Longeveron Inc. (LGVN) EV/Sales
As of 6 November 2026, Longeveron Inc. (LGVN) trades at a EV/Sales of −3.1×. Over the past ten years it has ranged from −4.2× (October 2026) to 347× (November 2021); the current reading is higher than 1% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.7× | 16.67% |
| FY2024 | 3.2× | (90.98%) |
| FY2023 | 34.9× | (19.52%) |
| FY2022 | 43.4× | (71.06%) |
| FY2021 | 150× | 613.59% |
| FY2020 | 21.0× | 0.00% |
| FY2019 | 21.0× | 0.00% |
| FY2018 | 21.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 10.8× | 21.05% |
| Mar 2026 | 8.9× | 141.70% |
| Dec 2025 | 3.7× | (1.55%) |
| Sep 2025 | 3.7× | (22.70%) |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LGVN Longeveron Inc. | −3.1× |
| SNTI Senti Biosciences, Inc. compare | −1.1× |
| CRIS Curis, Inc. compare | −0.3× |
| ACXP Acurx Pharmaceuticals, Inc. compare | n/m |
| XCUR Exicure, Inc. compare | 0.2× |
| PULM Pulmatrix, Inc. compare | 0.8× |
| CNSY Cerenome, Inc. compare | 1.5× |
| ORGS Orgenesis Inc. compare | 16.9× |
| PCSA Heatwurx Inc. compare | 49.5× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)